TransMedics Group (TMDX) Set to Announce Quarterly Earnings on Monday

TransMedics Group (NASDAQ:TMDX - Get Free Report) will announce its earnings results after the market closes on Monday, October 28th. Analysts expect the company to announce earnings of $0.28 per share for the quarter. TransMedics Group has set its FY 2024 guidance at EPS.Investors interested in registering for the company's conference call can do so using this link.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, topping the consensus estimate of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The firm had revenue of $114.30 million for the quarter, compared to analyst estimates of $98.84 million. During the same period last year, the business earned ($0.03) EPS. TransMedics Group's revenue for the quarter was up 117.7% compared to the same quarter last year. On average, analysts expect TransMedics Group to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

TransMedics Group Stock Down 1.7 %

NASDAQ:TMDX traded down $2.12 during midday trading on Monday, hitting $124.48. 1,192,392 shares of the company were exchanged, compared to its average volume of 835,844. The company has a fifty day simple moving average of $151.92 and a 200 day simple moving average of $139.08. TransMedics Group has a fifty-two week low of $36.42 and a fifty-two week high of $177.37. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67. The company has a market capitalization of $4.15 billion, a PE ratio of 3,112.00 and a beta of 1.99.

Analysts Set New Price Targets

TMDX has been the topic of several research reports. Piper Sandler reissued an "overweight" rating and set a $180.00 price objective on shares of TransMedics Group in a research report on Monday, October 7th. Canaccord Genuity Group raised their price objective on shares of TransMedics Group from $117.00 to $169.00 and gave the stock a "buy" rating in a research report on Thursday, August 1st. Robert W. Baird initiated coverage on shares of TransMedics Group in a research report on Tuesday, September 24th. They set an "outperform" rating and a $200.00 price objective on the stock. Baird R W raised shares of TransMedics Group to a "strong-buy" rating in a research report on Tuesday, September 24th. Finally, Needham & Company LLC assumed coverage on shares of TransMedics Group in a report on Wednesday, August 21st. They issued a "buy" rating and a $208.00 target price on the stock. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, TransMedics Group presently has a consensus rating of "Buy" and a consensus price target of $174.30.

Insider Buying and Selling

In related news, Director James R. Tobin sold 20,000 shares of the business's stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $159.33, for a total transaction of $3,186,600.00. Following the sale, the director now owns 173,146 shares of the company's stock, valued at approximately $27,587,352.18. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, Director James R. Tobin sold 20,000 shares of the business's stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $159.33, for a total transaction of $3,186,600.00. Following the sale, the director now owns 173,146 shares of the company's stock, valued at approximately $27,587,352.18. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Nicholas Corcoran sold 10,000 shares of the business's stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the sale, the insider now directly owns 21,105 shares in the company, valued at approximately $3,714,902.10. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 64,205 shares of company stock valued at $9,981,907. Corporate insiders own 7.00% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.